- Conditions
- Endometrial Neoplasms, Soft Tissue Sarcoma (STS), Breast Neoplasms
- Interventions
- AL58805, AL8326, Eribulin, Fulvestrant
- Drug
- Lead sponsor
- Advenchen Pharmaceuticals, LLC.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–2
of 2
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Small Cell Lung Cancer, Renal Cell Carcinoma (RCC), Non-Small Cell Lung
- Interventions
- AL8326 40 mg, AL8326 60 mg, AL8326 80 mg--stopped
- Drug
- Lead sponsor
- Advenchen Pharmaceuticals, LLC.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • Weston, Florida • Chicago, Illinois + 2 more